Califf Urges Congressional Patience On Opioid Actions

Labeling changes for the pain products remain in active discussion, the US FDA commissioner tells the Senate Health, Education, Labor and Pensions Committee during a hearing on the monkeypox outbreak.

Robert Califf at Senate HELP Committee hearing — Robert Califf was asked only a few questions about the monkeypox outbreak compared to other officials during a Senate committee hearing. • Source: Screenshot of Senate broadcast

Labeling changes remain possible as part of the US Food and Drug Administration’s new opioid policy, but are not coming fast enough in the eyes of some.

Commissioner Robert Califf told Sen. Maggie Hassan, D-N.H., during a 14 September hearing by the Senate Health, Education, Labor and...